Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair

Completed · Not applicable

Conditions studied: Aortic Aneurysm

In brief

The durability of endovascular aneurysm repair (EVAR) has been limited by development of endoleaks which may be secondary to progressive aortic degeneration by matrix metalloproteases (MMP). Doxycycline is a known inhibitor of the MMP family of enzymes in aneurysms. The investigators propose a randomized, controlled trial of adjuvant doxycycline therapy with EVAR to determine its effects on re-intervention, aneurysm shrinkage and serum markers of aneurysmal degeneration.

Key facts

Study ID

NCT00126204

Run by

The Foundation for Barnes-Jewish Hospital

People needed

75

Starts

2004-03-01

Expected to finish

2006-07-01

Last updated by the study team

2010-03-04

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Presence of an abdominal aortic aneurysm (AAA) with a maximum diameter of > or = 4.5 cm
• Planned aneurysm exclusion with endoluminal stent graft (any brand)

You may not qualify if…

• Known malignancy not to include prostate cancer or any history of cancer that has not had a recurrence in the last 5 years.
• Hypersensitivity to doxycycline or any of its components
• Pregnancy
• Ruptured AAA
• Extension of covered portion of the graft above the renal arteries
• Previous endoluminal aneurysm repair

Where it is running

• Washington University School of Medicine / Barnes-Jewish Hospital — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.